Clinical Trial
The objective of this clinical trial is to determine whether antidepressant medications, such as olanzapine, in combination with immune checkpoint inhibitors are more effective than the use of immune checkpoint inhibitors alone. The main questions it aims to answer are:
Is the combination therapy of antidepressant medication with immune checkpoint inhibitors more efficacious than the therapy with immune checkpoint inhibitors alone? What medical issues might participants encounter when treated with the combination of antidepressant medication and immune checkpoint inhibitors?
Participants will:
Take olanzapine in combination with immune checkpoint inhibitors or immune checkpoint inhibitors alone for 2 months.
Visit the clinic for check-ups and tests every two weeks, and have follow-up visits every six weeks after the treatment ends.
Keep a record of their symptoms and disease progression.
Participants voluntarily enroll in this study and sign an informed consent form, with good compliance and cooperation with follow-up.
Age is over 18 years old (including 18 years old) and under 75 years old (including 75 years old).
ECOG score: 0-2 points.
Expected survival is no less than 3 months.
Previously used any EGFR tyrosine kinase inhibitors;
Previously received any chemotherapy for lung cancer;
Previously received any radiotherapy for lung cancer (except palliative radiotherapy for bone metastases);
Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery;
Parallel
Olanzapine
DrugOlanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
Nivolumab
DrugNivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
The Overall Survival（OS）
The Overall Survival（OS），From the time of a patient's diagnosis or the commencement of treatment, to the time of the patient's death.
Click on the lead sponsor to view all of their trials.
